Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Meet Our Top Team of Endocrinologists


Crinetics was founded in endocrinology research and we’ve expanded our ranks with scientists and doctors who are leading experts in the field.

Alan S. Krasner, MD, Chief Medical Officer

  • Senior Medical Director/Global Development Lead, Shire Pharmaceuticals
  • Biodel, clinical researcher, diabetes/obesity
  • Pfizer, clinical researcher, diabetes/obesity
  • Northwestern University
  • Johns Hopkins University, Internal Medicine and Endocrinology

“Endocrinology is multi-dimensional. You have to think about the body holistically, As a company, Crinetics shares my point of view that it’s one thing to know all the hormonal fluctuations and their implications, but it’s also important to know what those fluctuations mean to an individual patient and how we can help that person get better, given that knowledge.”

peter trainer vice president clinical endocrinology crinetics

Peter Trainer, M.D., FRCPE, Vice President of Clinical Endocrinology

  • Honorary professor of endocrinology, University of Manchester (UK)
  • Clinical Director, Manchester Academic Health Science Centre
  • Director, Royal College of Physicians of Edinburgh
  • Associate Medical Director/Clinical Lead for endocrinology, The Christie NHS Foundation Trust
  • Sr Exec Committee member: Society for Endocrinology, the Endocrine Society & European Society of Endocrinology (ESE)

“I’ve been involved with a number of companies developing products for endocrinology disorders during my career. Crinetics’ ethos of science-driven innovation aligns perfectly with my interest and experience as a clinical scientist and in driving the translation of bench-top discovery through the developmental steps necessary for deployment for patient benefit.”

acasagrande 19 350x450 uai

Alessandra Casagrande, M.D., Ph.D.,Medical Sciences Director

  • Clinical researcher on rare diseases, Universidade Federal de Sao Paulo, Brazil
  • Researcher, Endocrinology,
    Rush University Medical Center and University of Illinois, Chicago
  • Medical Director, Rare Disease, pharmaceutical company, Sao Paulo, Brazil
  • Attending physician, Fleury Medicina Diagnóstica, Sao Paulo, Brazil
  • Clinical trials sub-investigator, Hospital de Clinicas, Porto Alegre, Brazil

“Neuroendocrinology has traditionally been an underserved discipline in that it doesn’t get the level of research funding many other disciplines do. I like that Crinetics recognized this from the start and pours so much effort and energy into making up for that. Rare endocrine diseases can have cascading effects on patients’ health and lives. Contributing to the solutions is rewarding work.”

Meet More Crinetizens

Let's Get Acromegaly on Your Radar


Acromegaly is a very rare disorder that develops when a benign tumor grows on the pituitary gland and secretes increased levels of growth hormone (GH) during adulthood. It can develop at any age but usually affects middle-aged adults.

Prevalence

About 25,000 patients in the U.S.

Incidence rate

3,000 new cases per year

Median age at diagnosis

40.5 – 47 years

Clinical manifestations of acromegaly can vary. Common changes in facial appearance can include a larger nose, fuller lips, a protruding lower jaw and brow, more numerous skin folds, and a general appearance of being unwell. Loss of peripheral vision is also possible as the tumor compresses the optic chiasm. Patients may report newly developed difficulty parallel parking, a general fogginess or forgetfulness, and other symptoms, as seen in this chart.

Current medical therapies require painful monthly injections that disrupt patients’ lives, or oral medication that calls for a dietary regimen that can be difficult to maintain. Crinetics is developing a once-daily oral treatment for acromegaly called paltusotine that may offer patients a better option.

Learn More About Paltusotine
acromegaly symptoms chart uai

We Are Here For the Patients


To us, patients are more than the symptoms they have or the treatments they’re on. You are partners in this work. Real people with friends and families…ideas and insights…hobbies and hopes. Most of all, you have important contributions to make as we pursue solutions that will impact your life. That’s why we pledge to bring five key qualities to every patient relationship:

rick copy uai

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Watch Patients Talk About Acromegaly

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Watch Patients Talk About Acromegaly

Read the Latest


Crinetics Announces Closing of Common Stock Offering

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock.

Crinetics Announces Pricing of Common Stock Offering

Paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated

2021 Clinical Plans, 4th Quarter, and 2020 Financial Results

Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020.

Webcast: 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020.